Erik A. Ranheim

University of Wisconsin–Madison — United States

Immunology and Microbiology · Life Sciences

37h-index4.1kcitations189works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(49), CAR-T cell therapy research(45), Acute Myeloid Leukemia Research(34), Lymphoma Diagnosis and Treatment(31), Cutaneous Melanoma Detection and Management(26)

Publications188 total

Boosting anti-tumor immunity in NRAS;ASXL1-driven Acute Myeloid Leukemia through combined inhibition of MEK and HDACs.
Blood·2025Open Access
Abstract 2226: Combined inhibition of MEK and HDACs improves the cytotoxicity of CD4 and CD8 T cells in NRAS;ASXL1-driven acute myeloid leukemia mice
Cancer Research·2025
Beyond the Screen: Navigating Remote Work within Medicine
Clinical Chemistry·2024· 1 cited
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma
Melanoma Research·2024· 6 citedOpen Access
To Grade or Not to Grade (the Quiz): The Impact of Two Formative Assessment Grading Approaches on Summative Assessment Outcomes in an Integrated Pre-clinical Curriculum
Medical Science Educator·2024· 1 cited
Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice
PLoS Pathogens·2024· 6 citedOpen Access
Subperiosteal delivery of transforming growth factor beta 1 and human growth hormone from mineralized <scp>PCL</scp> films
Journal of Biomedical Materials Research Part A·2024
A gain-of-function p53 mutant synergizes with oncogenic NRAS to promote acute myeloid leukemia in mice
Journal of Clinical Investigation·2023· 14 citedOpen Access
Exploring Racial Differences in Disease Prevalence in a Preclinical Curriculum
Academic Medicine·2023
Pdx1 expression in hematopoietic cells activates <i>Kras</i> -mutation to drive leukemia in KC ( <i> Pdx1-Cre; LSL-Kras <sup>G12D/+</sup> </i> ) mice
Leukemia & lymphoma/Leukemia and lymphoma·2023· 1 citedOpen Access
Supplemental Figure SF-10 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
2023Open Access
Supplemental Figure SF-13 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
2023Open Access
Supplemental Figure SF-01 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
2023Open Access
Supplemental Figure SF-15 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
2023Open Access
Data from A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408
2023Open Access
Supplemental Figure SF-04 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
2023Open Access
Supplemental Methods and Figure Legends from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
2023Open Access
Supplemental Figure SF-02 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
2023Open Access
Supplemental Figure SF-16 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
2023Open Access
Supplemental Figure SF-15 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Guangyao Kong(11), Jing Zhang(9), Yun Zhou(8), Xiaona You(7), Jinyong Wang(6), Paul M. Sondel(5), Kirby D. Johnson(5), Emery H. Bresnick(5), Shannon C. Kenney(5), Thomas J. Kipps(4), Eric Padron(4), Juan Du(4), Jacquelyn A. Hank(4), Xin Gao(4), Yuan-I Chang(4), Alisa Damnernsawad(4), Randy D. Gascoyne(4), David T. Yang(4), Adhithi Rajagopalan(4), James C. Romero-Masters(4)